NCI Launches Randomized Trial of Shark Cartilage in NSCLC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

BETHESDA, Md-Enrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.

BETHESDA, Md—Enrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.

The randomized, double-blind, placebo-controlled study, supported by the National Cancer Institute, anticipates enrolling 756 patients within the next 3 years at more than 50 sites in the United States and Canada.

Articles in this issue
NCI to Expand Its Support for Trials of STI-571
Patients and Physicians Differ on Chemotherapy Expectations
Neoadjuvant Weekly Paclitaxel Ups Breast Cancer Pathologic Complete Response Rates
Concurrent Chemoradiotherapy Helps Preserve Larynx
Once-Daily, Rapid-Onset Morphine Offers Alternative for Those in Severe Pain
FDA Issues New Safeguards for Children in Clinical Trials
Decision Board Helps Breast Cancer Patients Assess Chemotherapy Options, Increases Satisfaction
Over 20% of Breast Cancer Patients Risk Recurrence by Not Taking Their Tamoxifen
Selective Serotonin Reuptake Inhibitors Can Successfully Treat Depression But Not Fatigue in Cancer Patients
Leukemia Society Offers Patient Information on Use of STI-571
Hiking Cigarette Prices Discourages Teens From Taking Up the Habit
Consensus Growing for SV40 Role in Some Mesotheliomas
NCI Launches Randomized Trial of Shark Cartilage in NSCLC
Chemotherapy Common at End of Life
Can Cognitive Dysfunction in Breast Cancer Patients Be Prevented?
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content
The blood-based test detected 31% of lung cancers 1 year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Blood-Based Screening Test May Increase Preclinical Lung Cancer Detection

Roman Fabbricatore
November 22nd 2025
Article

The blood-based test detected 31% of lung cancers one year prior to in-trial diagnosis compared with 8% of cancers identified by low-dose CT or Lung-RADS.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Imneskibart Yields Activity and Responses in Melanoma, NSCLC Cohorts

Russ Conroy
November 11th 2025
Article

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.